Blog Articles
Whole-genome and whole-transcriptome sequencing for sarcoma diagnosis
February 2025
Whole-genome and Whole-transcriptome sequencing (WGTS) improve the diagnosis of sarcomas. Read our article to learn more.
Conference Spotlight: A whole-genome-sequencing workflow with high sensitivity for MRD detection
November 2024
At the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, Illumina presents the ongoing development of a research-use-only WGS workflow for MRD detection.
Whole-genome sequencing in AML diagnosis and monitoring
October 2023
Whole-genome sequencing (WGS) has the potential to transform the diagnosis and management of AML. Read our article to learn more.
Conference Spotlight: Prospective study supports use of WGTS in routine diagnostics of bone and soft tissue tumors.
July 2023
From ESMO Sarcoma and Rare Cancers Congress 2023, an evaluation study by Karolinska Institute of Whole Genome and Transcriptome Sequencing (WGTS) for routine diagnosis of bone or soft tissue tumors.
Cancers of Unknown Primary
March 2023
Cancers of unknown primary (CUP), also known as occult primary tumors, comprise a heterogenous group of metastatic neoplasms where the primary site of cancer cannot be determined, despite a thorough workup[1].
Enabling Precision medicine in Oncology through full genome and transcriptome analysis
June 2022
Cancer is a disease of the genome, where the combination of acquired genetic, epigenetic and inherited germline changes can lead to the proliferation and survival of cancer cells.
Upgrade your browser or select an alternate
Chrome
Firefox
Safari
Edge